Aligos Therapeutics is discovering and developing new classes of molecules that interact directly with disease-causing modalities such as viral encoded proteins and nucleic acids, as well as oncogenes and their resultant proteins in the case of our cancer indications. The company is also pursuing novel therapeutic agents aimed at activation of the patients immune system, to create lasting benefits for the diseases that cause significant morbidity and mortality.